Thomas Bures - 22 Feb 2022 Form 4 Insider Report for PIERIS PHARMACEUTICALS, INC. (PVLA)

Reporting relationship: Chief Financial Officer
Issuer ticker: PVLA
Reported as of: 22 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2022, 15:46:43 UTC
Next SEC filing: 28 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Megan Gates, Attorney-in-Fact

Key filing fact

Thomas Bures filed Form 4 for PIERIS PHARMACEUTICALS, INC. (PVLA) on 24 Feb 2022.

Key facts

This page summarizes Thomas Bures's Form 4 filing for PIERIS PHARMACEUTICALS, INC. (PVLA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2022, 15:46.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PIRS transaction Derivative

Stock Options (Right to buy)

Award

Transaction value: $0
Shares: +215,819
Change %
Price: $0.000000
Shares after: 215,819
Date: 22 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 215,819
Exercise price: $3.03
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests as to 25% of the option shares on February 22, 2023 and as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter.